Admin Posted June 23, 2018 Share Posted June 23, 2018 Jim Marshall (not a doctor) said ... Radioactive Lutetium is being trialled in a few places around the world as a treatment for end-stage, progressive, metastatic, castrate resistant prostate cancer. The current best treatment for end-stage, progressive, metastatic, castrate resistant prostate cancer is a chemotherapy drug Jevtana (Cabazitaxel). Phase I and II trials look to see if a treatment is safe. Phase III trials test it against the best current treatment. A new trial of Lutetium-177 has started in the USA. The trial is called PROter. Phoenix Molecular Imaging Center is the only listed location on ClinicalTrials.gov so far. The trial is phase I/II, looking at safety and best dose for later phase III trials. PSMA is a compound found on the surface of many prostate cells. Prostate cancer cells often have more than 10 times as much PSMA on their surfaces than ordinary prostate cells. All radioactive Lutetium treatments consist of: a PSMA grabber; a joiner; and radioactive Lutetium. The PSMA grabber grabs on to PSMA on the cell surface, bringing the radioactive Lutetium close enough to damage the cell. It seems from the press release that the joiner in the PROter trial is called R2. PSMA = Prostate Specific Membrane Antigen Thanks to Alan Barlee for bringing this to our attention ... end Jim Link to comment Share on other sites More sharing options...
This topic is now archived and is closed to further replies.